B

Bioretec Oy
OMXH:BRETEC

Watchlist Manager
Bioretec Oy
OMXH:BRETEC
Watchlist
Price: 2.14 EUR 7% Market Closed
Market Cap: 49.9m EUR
Have any thoughts about
Bioretec Oy?
Write Note

Bioretec Oy
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bioretec Oy
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
B
Bioretec Oy
OMXH:BRETEC
Income from Continuing Operations
-€3.7m
CAGR 3-Years
-18%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
R
Revenio Group Oyj
OMXH:REG1V
Income from Continuing Operations
€19.1m
CAGR 3-Years
3%
CAGR 5-Years
19%
CAGR 10-Years
22%
M
Modulight Oyj
OMXH:MODU
Income from Continuing Operations
-€11.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
O
Optomed Oyj
OMXH:OPTOMED
Income from Continuing Operations
-€4.4m
CAGR 3-Years
-12%
CAGR 5-Years
-27%
CAGR 10-Years
N/A
N
Nexstim Oyj
OMXH:NXTMH
Income from Continuing Operations
-€833.1k
CAGR 3-Years
40%
CAGR 5-Years
35%
CAGR 10-Years
N/A
B
Biohit Oyj
OMXH:BIOBV
Income from Continuing Operations
€1.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Bioretec Oy
Glance View

Market Cap
49.9m EUR
Industry
Health Care

Bioretec Ltd. develops bioabsorbable and bioresorbable implants for pediatric and adult orthopaedics. The company is headquartered in Tampere, Lansi-Suomen. The company went IPO on 2021-09-28. The firm operates as a developer, manufacturer and commercializer of innovative bioresorbable orthopedic implants and implant materials used for the treatment of bone and soft tissue injuries. Bioretec Oy’s existing Activa product portfolio consists of bioabsorbable biopolymer products that are alreadyavailable in the market for applications in pediatrics, trauma surgery as well as sports surgery. Bioretec Oy has one Germany-based subsidiary, BRI.Tech GmbH. The Company’s products are used all over the world.

BRETEC Intrinsic Value
3.33 EUR
Undervaluation 36%
Intrinsic Value
Price
B

See Also

What is Bioretec Oy's Income from Continuing Operations?
Income from Continuing Operations
-3.7m EUR

Based on the financial report for Dec 31, 2023, Bioretec Oy's Income from Continuing Operations amounts to -3.7m EUR.

What is Bioretec Oy's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-13%

Over the last year, the Income from Continuing Operations growth was -54%. The average annual Income from Continuing Operations growth rates for Bioretec Oy have been -18% over the past three years , -13% over the past five years .

Back to Top